PMID- 30783475
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200929
IS  - 1792-0981 (Print)
IS  - 1792-1015 (Electronic)
IS  - 1792-0981 (Linking)
VI  - 17
IP  - 3
DP  - 2019 Mar
TI  - Candidate genes associated with the effect of rosiglitazone on glycemic control 
      and cardiovascular system in the treatment of type 2 diabetes mellitus.
PG  - 2039-2046
LID - 10.3892/etm.2019.7160 [doi]
AB  - In the present study, candidate genes affected by rosiglitazone to exert glycemic 
      control in the treatment of type 2 diabetes mellitus (T2DM) and associated with 
      its adverse cardiovascular effects were identified using a bioinformatics 
      analysis. The gene expression profiles of the dataset GSE36875 from the Gene 
      Expression Omnibus database, including heart samples from 5 non-diabetic control 
      mice (NC), 5 untreated diabetic mice (NH) and 5 rosiglitazone-treated diabetic 
      mice (TH), were used to identify differentially expressed genes (DEGs) in the NC 
      vs. NH, NC vs. TH and TH vs. NH groups. Subsequently, Kyoto Encyclopedia of Genes 
      and Genomes (KEGG) pathways enriched by the DEGs were determined. Furthermore, 
      genes associated with the action of rosiglitazone were identified using Short 
      Time-series Expression Miner, which were then subjected to enrichment analysis in 
      gene ontology (GO) terms in the category biological process (BP), and networks of 
      the GO terms, KEGG pathways and genes associated with the action of rosiglitazone 
      were constructed. Finally, biological abnormalities associated with these genes 
      were identified using WebGestalt. A set of 791 DEGs in three groups (NC vs. NH, 
      NC vs. TH and NH vs. TH) were identified. Subsequently, 72 DEGs [e.g., 
      apolipoprotein (Apo)A1, ApoA5, cytochrome P450 (Cyp)2c37, Cyp2J5, Cyp2b9 and 
      Cyp2b10] were identified as genes associated with the action of rosiglitazone. In 
      addition, a network of 13 GO terms in the category BP, 6 KEGG pathways and 41 
      genes associated with the action of rosiglitazone was constructed, with major 
      terms/pathways including oxidation/reduction, lipid transport, peroxisome 
      proliferator-activated receptor signaling pathway and metabolism of xenobiotics 
      by Cyp. Finally, 15 biological abnormalities (including abnormal triglyceride 
      levels, abnormal cholesterol homeostasis, abnormal lipid homeostasis) associated 
      with these genes were identified. ApoA1, ApoA5, Cyp2c37, Cyp2J5, Cyp2b9 and 
      Cyp2b10 were differently expressed after rosiglitazone treatment, which may be 
      accountable for affecting cardiovascular outcomes and glycemic control in T2DM. 
      The present results may expand the current understanding of the mechanism of 
      action of rosiglitazone to exert glycemic control in T2DM, as well as its effects 
      on the cardiovascular system.
FAU - Wu, Xiaoli
AU  - Wu X
AD  - Department of Pharmacy, Huai'an First People's Hospital, Nanjing Medical 
      University, Huai'an, Jiangsu 223300, P.R. China.
LA  - eng
PT  - Journal Article
DEP - 20190109
PL  - Greece
TA  - Exp Ther Med
JT  - Experimental and therapeutic medicine
JID - 101531947
PMC - PMC6364243
OTO - NOTNLM
OT  - cytochrome P450
OT  - diabetic heart
OT  - lipid transport
OT  - oxidation/reduction
OT  - peroxisome proliferator-activated receptor signaling pathway
OT  - rosiglitazone
EDAT- 2019/02/21 06:00
MHDA- 2019/02/21 06:01
PMCR- 2019/01/09
CRDT- 2019/02/21 06:00
PHST- 2018/03/11 00:00 [received]
PHST- 2018/11/01 00:00 [accepted]
PHST- 2019/02/21 06:00 [entrez]
PHST- 2019/02/21 06:00 [pubmed]
PHST- 2019/02/21 06:01 [medline]
PHST- 2019/01/09 00:00 [pmc-release]
AID - ETM-0-0-7160 [pii]
AID - 10.3892/etm.2019.7160 [doi]
PST - ppublish
SO  - Exp Ther Med. 2019 Mar;17(3):2039-2046. doi: 10.3892/etm.2019.7160. Epub 2019 Jan 
      9.